MYASTHENIA GRAVIS, THYMOMA, AND THYMOMECTOMY: THE CLINICAL INTERPLAY.
DOI:
https://doi.org/10.5455/ijcbr.2018.42.17Abstract
Myasthenia gravis is an autoimmune disorder that places patients in debilitating condition. It currently affects 14 to 20 per 100,000 population. Its pathogenesis involves the destruction of acetylcholine receptor by antibodies produced by lymphocytes in the thymus gland. Symptoms could vary from impair extraocular muscles to generalized weakness. The antibodies have also been reported to affect other muscle structure within the body such as cardiomyocytes, leading to arrhythmia episodes which could be fatal. This review is a student project and involves the assessment of myasthenia gravis and the interplay between thymoma and thymomectomy.Downloads
References
Murai H, Yamashita N, Watanabe M, Nomura Y, Motomura M, Yoshikawa H et al. Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. Journal of the Neurological Sciences. 2011;305(1-2):97-102.
Huang K, Luo Y, Yang H, Yang X, Li J. Myasthenia gravis accompanied by Graves' disease, thyrotoxic hypokalemic periodic paralysis and thymic hyperplasia. Neurology India. 2016;64(4):783.
Karni A, Asmail A, Drory V, Kolb H, Kesler A. Characterization of patients with ocular myasthenia gravis — A case series. eNeurologicalSci. 2016;4:30-33.
Marx A, Porubsky S, Belharazem D, Saruhan-Direskeneli G, Schalke B, Ströbel P et al. Thymoma related myasthenia gravis in humans and potential animal models. Experimental Neurology. 2015;270:55-65.
Bruno R. Different patterns of nicotinic acetylcholine receptor subunit transcription in human thymus. Journal of Neuroimmunology. 2004;149(1-2):147-159.
Chu D, Johnson R, Pun S. Cathepsin B-sensitive polymers for compartment-specific degradation and nucleic acid release. Journal of Controlled Release. 2012;157(3):445-454.
Casciola-Rosen L, Miagkov A, Nagaraju K, Askin F, Jacobson L, Rosen A et al. Granzyme B: Evidence for a role in the origin of myasthenia gravis. Journal of Neuroimmunology. 2008;201-202:33-40.
Evoli A, Batocchi A, Minisci C, Di Schino C, Tonali P. Therapeutic options in ocular myasthenia gravis. Neuromuscular Disorders. 2001;11(2):208-216.
Cho E, Min J, Lee S, Yoon C, Seok J, Cho H et al. Late-onset non-thymomatous myasthenia gravis: Comparison with early-onset and very late-onset myasthenia gravis. Neurology Asia. 2017;22(2):123-131.
Meyer A, Levy Y. Chapter 33: Geoepidemiology of myasthenia gravis. Autoimmunity Reviews. 2010;9(5):A383-A386.
Aarli J. Titin, Thymoma, and Myasthenia Gravis. Archives of Neurology. 2001;58(6):869.
López-Cano M, Ponseti-Bosch J, Espin-Basany E, Sánchez-GarcÃa J, Armengol-Carrasco M. Clinical and pathologic predictors of outcome in Thymoma-Associated myasthenia gravis. The Annals of Thoracic Surgery. 2003;76(5):1643-1649.
Willcox N. Thymus and Thymoma in Myasthenia Gravis Patients. The Thymus Gland. :33-39.
Conti-Fine B, Milani M, Kaminski H. Myasthenia gravis: past, present, and future. Journal of Clinical Investigation. 2006;116(11):2843-2854.
Maggi L, Andreetta F, Antozzi C, Baggi F, Bernasconi P, Cavalcante P et al. Thymoma-associated myasthenia gravis: Outcome, clinical and pathological correlations in 197 patients on a 20-year experience. Journal of Neuroimmunology. 2008;201-202:237-244.
Romi F. Thymoma in Myasthenia Gravis: From Diagnosis to Treatment. Autoimmune Diseases. 2011;2011:1-5.
Lin J, Lu J, Zhao C, Qiao K, Zhu W, Yue D et al. Giant cell polymyositis associated with myasthenia gravis and thymoma. Journal of Clinical Neuroscience. 2014;21(12):2252-2254.
Wolfe G, Kaminski H, Aban I, Minisman G, Kuo H, Marx A et al. Randomized Trial of Thymectomy in Myasthenia Gravis. New England Journal of Medicine. 2016;375(6):511-522.
Aydin Y, Ulas A, Mutlu V, Colak A, Eroglu A. Thymectomy in Myasthenia Gravis. The Eurasian Journal of Medicine. 2017;49(1):48-52.
Downloads
Published
Issue
Section
License
The journal allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.
The submitted papers are assumed to contain no proprietary material unprotected by patent or patent application; responsibility for technical content and for protection of proprietary material rests solely with the author(s) and their organizations and is not the responsibility of the journal. The main (first/corresponding) author is responsible for ensuring that the article has been seen and approved by all the other authors. It is the responsibility of the author to obtain all necessary copyright release permissions for the use of any copyrighted materials in the manuscript prior to the submission.
What are my rights as an author?
It is important to check the policy for the journal to which you are submitting or publishing to establish your rights as
Author. Journal's standard policies allow the following re-use rights:
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to obtain publishing rights without restrictions.
- You may do whatever you wish with the version of the article you submitted to the journal.
- Once the article has been accepted for publication, you may post the accepted version of the article on your own personal website, your department's website or the repository of your institution without any restrictions.
- You may not post the accepted version of the article in any repository other than those listed above (i.e. you may not deposit in the repository of another institution or a subject-matter repository) until 12 months after publication of the article in the journal.
- You may use the published article for your own teaching needs or to supply on an individual basis to research colleagues, provided that such supply is not for commercial purposes.
